Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. Cohen M, et al. Among authors: bigonzi f. N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702. N Engl J Med. 1997. PMID: 9250846 Free article. Clinical Trial.
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. Cohen M, et al. Among authors: bigonzi f. Am J Cardiol. 1998 Sep 10;82(5B):19L-24L. doi: 10.1016/s0002-9149(98)00108-8. Am J Cardiol. 1998. PMID: 9737476 Clinical Trial.
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
Goodman SG, Cohen M, Bigonzi F, Gurfinkel EP, Radley DR, Le Iouer V, Fromell GJ, Demers C, Turpie AG, Califf RM, Fox KA, Langer A. Goodman SG, et al. Among authors: bigonzi f. J Am Coll Cardiol. 2000 Sep;36(3):693-8. doi: 10.1016/s0735-1097(00)00808-1. J Am Coll Cardiol. 2000. PMID: 10987586 Free article. Clinical Trial.
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Cohen M, Maritz F, Gensini GF, Danchin N, Timerman A, Huber K, Gurfinkel EP, White H, Fox KA, Vittori L, Le-Louer V, Bigonzi F. Cohen M, et al. Among authors: bigonzi f. J Thromb Thrombolysis. 2000 Dec;10(3):241-6. doi: 10.1023/a:1026543107533. J Thromb Thrombolysis. 2000. PMID: 11122544 Clinical Trial.
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F; ACUTE II Investigators. Cohen M, et al. Among authors: bigonzi f. Am Heart J. 2002 Sep;144(3):470-7. doi: 10.1067/mhj.2002.126115. Am Heart J. 2002. PMID: 12228784 Clinical Trial.
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Cohen M, Gensini GF, Maritz F, Gurfinkel EP, Huber K, Timerman A, Krzeminska-Pakula M, Danchin N, White HD, Santopinto J, Bigonzi F, Hecquet C, Vittori L; TETAMI Investigators. Cohen M, et al. Among authors: bigonzi f. J Am Coll Cardiol. 2003 Oct 15;42(8):1348-56. doi: 10.1016/s0735-1097(03)01040-4. J Am Coll Cardiol. 2003. PMID: 14563573 Free article. Clinical Trial.
19 results